Benitec Biopharma, which is developing gene therapies for hepatitis C based on RNA interference, announced terms for its IPO on Monday.
The Balmain, Australia-based company plans to raise $65 million by offering 5 million shares at a price range of $13.06 to $13.06. At the midpoint of the proposed range, Benitec Biopharma would command a fully diluted market value of $141 million.
Benitec Biopharma, which was founded in 1995, plans to list on the Nasdaq under the symbol BNTC. BMO Capital Markets is the sole bookrunner on the deal. It is expected to price during the week of August 3, 2015.
